Editas Medicine Stock Forecast
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 2.89 -0.34%
EDIT analyst consensus
Consensus (13 analysts)
buy
Avg. price target
$5.90+103.45%
- Strong buy 0
- Buy 8
- Hold 3
- Sell 0
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Editas Medicine (2026-10-08), 8 rate the stock a buy or strong buy, 3 rate it a hold and 2 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $5.90, with a high estimate of $15.00 and a low estimate of $1.00. The average target implies upside of 103.4% from the current price of $2.90.
The spread between the highest and lowest targets is 1400.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for EDIT.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 8 | 62% |
| Hold | 3 | 23% |
| Sell | 0 | 0% |
| Strong sell | 2 | 15% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $1.00 | -65.52% |
| Average target | $5.90 | +103.45% |
| High target | $15.00 | +417.24% |